摘要
目的探讨17β雌二醇在激素替代内膜准备冻融胚胎移植（FET）中的应用并与戊酸雌二醇进行比较，探讨不同内膜厚度及雌激素（E2）水平对临床结局的影响。方法收集2012年1至6月在浙江大学医学院附属邵逸夫医院生殖中心行激素替代（HRT）内膜准备FET周期1072个，根据使用的药物类型分两组：A组：仅使用戊酸雌二醇准备内膜（798个周期）；B组：如仅使用戊酸雌二醇不能达到满意的内膜厚度及E2水平，或反复移植失败，则采用戊酸雌二醇＋17β雌二醇准备内膜（274个周期），比较两种内膜准备方案患者的基本情况及临床结局的差异。比较内膜厚度及E2不同分层临床结局的差异，并将B组内膜〈7mm与2011年相同内膜厚度的患者比较。结果A组第1次移植比例、内膜准备周期的平均内膜厚度均显著高于B组，并且〈7mm比例B组8．8％，A组2．4％，差异有统计学意义。但两组总临床妊娠率（54．8％比52．9％）、胚胎种植率（38．1％比35．8％）差异无统计学意义。随内膜增厚，胚胎种植率和临床妊娠率呈上升趋势；不同E2水平间的临床结局差异均无统计学意义；而B组内膜〈7mm的病例与2011年HRT周期相同内膜厚度（均仅用戊酸雌二醇）比较结果提示，戊酸雌二醇＋17β雌二醇方案的临床妊娠率、胚胎种植率及活胎产率均要高于2011年，差异无统计学意义。结论对于子宫内膜薄，单纯使用戊酸雌二醇不能获得满意内膜厚度或理想雌激素水平的患者，在FET的HRT内膜准备中可以加用17β雌二醇阴道吸收，能增加内膜厚度，改善内膜容受性，从而获得较理想的临床结局。
Objective To explore the application of Femoston in hormone replacement treatment- frozen embryo transfer （HRT-FET） versus endometrial preparation with Progynova and examine the effects of different endometrial thickness and estradiol levels on clinical outcomes. Methods Retrospective analysis was conducted for a total of 1072 HRT-FET cycles at our center during January-June 2012. According to the type of medication, the patients were divided into 2 groups： Group A： Progynova only （798 cycles）. Group B： non-satisfactory endometrial thickness or E2 level only by Progynova or repeated implantation failure, Progynova plus Femoston for preparing endometrium （274 cycles）. Then the inter-group differences of basic profiles and clinical outcomes were compared. Comparison of clinical outcomes was performed based on different estradiol （E2） levels and endometrial thickness on the day of using progesterone. And then, the patients whose endometrial double thickness was thinner than 7 mm in Progynova ＋ Femoston group were compared with the group of similar endometrial thickness in 2011. The data were analyzed with SPSS 16. O. Results In Group A, the percentage of first transfer, average endometrial thickness on the day of using progesterone in FET cycles were all significantly higher than Group B. And the ratio of 〈 7 mm was significantly higher in Group B （8. 8% vs 2. 4% ）. However, no significant differences existed in clinical pregnancy rate （54. 8% vs 52. 9% ） or embryo implantation rate （38.1% vs 35.8% ）. With endometrial thickening, both clinical pregnancy and embryo implantation rates increased. There was no significant difference in maximum E2 level. Clinical pregnancy rate, embryo implantation rate and live birth rate of the patients whose endometrial double thickness was thinner than 7 mm in Group B were all higher than those of similar endometrial thickness （all Progynova only） in 2011. Conclusion For patients with thin endometrium, vaginal Femoston may be added if ideal endometrial thickness or E2 level is not achieved by Progynova alone. It improves endometrial receptivity and clinical outcomes are more satisfactory.
出处
《中华医学杂志》
CAS
CSCD
北大核心
2013年第47期3766-3769,共4页
National Medical Journal of China
基金
卫生部科学研究基金-浙江省医药卫生重大科技计划（WKJ2012-2-028）
关键词
激素替代治疗
内膜厚度
雌二醇
临床妊娠率
Hormone replacement therapy
Endometrial thickness
Estradiol
Clinical pregnancy rate
